These effects indicate that SLC34A2 might be engaged in tumor progression, which was confirmed by studies showing that SLC34A2 promotes proliferation and chemoresistance in colorectal cancer through reactive oxygen species (ROS)–hypoxia‐inducible factor 1‐induced enhancer of zeste homolog 2 upregulation 10, that SLC34A2 facilitates the progression of human osteosarcoma cells through phosphatase and tensin homologue–phosphoinositide 3‐kinase–Akt signaling 11, and that SLC34A2 enhances hepatocellular carcinoma cell proliferation and invasion 12. The gene discussed is SLC34A2; the disease is colorectal cancer.